Y-mAbs Therapeutics

YMAB64

$10.77arrow_drop_up1.98%$0.20

YMAB64

$10.77

arrow_drop_up1.98%$0.20

Performance History

Key Stats
Open	$10.54
Prev. Close	$10.56
EPS	-0.54
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	10.39	12.08
52 Week Range	4.69	20.90

Ratios







EPS	-0.54

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Y-mAbs Therapeutics (YMAB)

Y-mAbs Therapeutics Inc (YMAB) is a biopharmaceutical company that specializes in the development and commercialization of innovative antibody-based therapies for the treatment of pediatric and adult cancers. The company's mission is to improve the lives of patients by addressing unmet medical needs in the field of oncology. With a strong focus on precision medicine, YMAB aims to deliver targeted therapies that have the potential to provide better outcomes and fewer side effects compared to traditional treatments.

One of the key strengths of YMAB is its robust pipeline of product candidates, which includes both monoclonal antibodies and bispecific antibodies. These therapies are designed to selectively target cancer cells while sparing normal cells, thereby enhancing their efficacy and minimizing toxicity. The company's lead product candidate, naxitamab, is being evaluated for the treatment of neuroblastoma, a rare and aggressive form of childhood cancer. Naxitamab has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and is currently in late-stage clinical trials.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Thomas Gad
Headquarters: New York
Employees: 147
Exchange: NASDAQ

Keep an eye on Y-mAbs Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Y-mAbs Therapeutics (YMAB) stock price performance year to date (YTD)?

As of the latest data, Y-mAbs Therapeutics (YMAB) has a year-to-date price change of 56.77%. Over the past month, the stock has experienced a price change of -27.28%. Over the last three months, the change has been -28.82%. Over the past six months, the figure is -11.29%. Looking at a longer horizon, the five-year price change stands at -66.88%.

help

What is Y-mAbs Therapeutics 's (YMAB) price per share?

The current price per share for Y-mAbs Therapeutics (YMAB) is $10.77. The stock has seen a price change of $0.21 recently, indicating a 1.99% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Y-mAbs Therapeutics (YMAB)?

For Y-mAbs Therapeutics (YMAB), the 52-week high is $20.9, which is 94.06% from the current price. The 52-week low is $4.69, the current price is 129.64% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Y-mAbs Therapeutics (YMAB) a growth stock?

Y-mAbs Therapeutics (YMAB) has shown an average price growth of -3.4% over the past three years. It has received a score of 68 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Y-mAbs Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

Is Y-mAbs Therapeutics (YMAB) a profitable company?

Y-mAbs Therapeutics (YMAB) has a net income of -$21.43M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 86.54% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -42.52% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $84.82M, with a revenue growth rate of 29.96%, providing insight into the company's sales performance and growth. The gross profit is $73.4M. Operating income is noted at -$25.67M. Furthermore, the EBITDA is -$23.35M.

help

What is the market capitalization of Y-mAbs Therapeutics (YMAB)?

Y-mAbs Therapeutics (YMAB) has a market capitalization of $482.38M. The average daily trading volume is 10.8, indicating the stock's liquidity and investor engagement.